IMPLANET Announces 9-month Revenue of €6 Million as of September 30, 2022, up +37%
-
Revenue increase driven by business in
France and the rest of the world, which grew by40% and73% respectively
- Third consecutive quarter of revenue growth
-
Success of the proposed capital increase with preferential subscription rights for
€ 2.77 million
In K€ - IFRS standards1 |
2022 |
|
2021 |
|
Variation |
|
Total 1st quarter revenue |
2,016 |
|
1,026 |
|
+ |
|
Total 2nd quarter revenue |
2,096 |
|
1,575 |
|
+ |
|
3rd quarter |
|
|
|
|
|
|
|
691 |
|
750 |
|
- |
|
|
476 |
|
409 |
|
+ |
|
Rest of the World |
696 |
|
617 |
|
+ |
|
Spine 3rd quarter revenue |
1,863 |
|
1,775 |
|
+ |
|
Knee & Artho 3rd quarter revenue |
-1 |
|
- |
|
|
|
Total 3rd quarter revenue |
1,862 |
|
1,775 |
|
+ |
|
TOTAL 9-Month |
|
|
|
|
|
|
|
2,492 |
|
1,785 |
|
+ |
|
|
1,278 |
|
1,302 |
|
- |
|
Rest of the World |
2,183 |
|
1,265 |
|
+ |
|
Spine 9 months revenue |
5,952 |
|
4,352 |
|
+ |
|
Knee & Artho 9 months revenue |
22 |
|
23 |
|
- |
|
Total 9-month revenue |
5,974 |
|
4,375 |
|
+ |
*Unaudited figures
Third quarter of 2022
During the third quarter of 2022, the activity recorded a +
Despite the fact that business in
-
a
17% increase in sales inthe United States , to€0.48 million from€0.41 million in the third quarter of 2021, enabling the company to return to an annual sales rate of€2.0 million in this territory. This growth is also marked by the resumption of orders and deliveries to SeaSpine.
-
the acceleration of commercial development in the rest of the world, with growth of +
13% , to reach€0.70 million compared to€0.62 million for the same period in 2021.
First nine months of 2022
In the first nine months of 2022, the activity increased by a factor of 1.4, i.e. by +
In
In the rest of the world, the export activity has been multiplied by 1.7, going from 1.27 M€ in 2021 to 2.18 M€.
Cash position
Following the success of the capital increase with preferential subscription rights announced on
With these new financial resources, the Company has also decided to put an end to the issuance of new convertible bonds within the framework of the financing line, ensured by the company Nice & Green and signed on
2022 Highlights
-
First surgeries in
the United States with JAZZ™ PF, an innovative solution from the JAZZ® line
-
First surgeries in the
U.S. with the ORIGIN Cervical Spine Plate marking the first successful synergies with OSD products
-
Signature of a commercial, technological and financial partnership with Sanyou Medical, the second largest Chinese manufacturer of medical devices for spinal surgery:
-
Distribution agreement for
Implanet's JAZZ® platform inChina , the world's largest market (by volume) for spine surgery; - Technology partnership: joint development of a new European range of hybrid fastening systems;
-
Financial partnership: proposed capital increase with preferential subscription rights through the issue of shares with warrants attached (ABSA), guaranteed to the tune of
€5 million by the partner Sanyou Medical.
-
Distribution agreement for
-
Success of the capital increase with preferential subscription rights for shareholders for an amount of
€ 2.77 million .
Upcoming financial event:
-
2022 annual Revenue,
January 17, 2023 , after market close
About
Founded in 2007,
1 Unaudited figures
View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005600/en/
Tel: 05 57 99 55 55
investors@implanet.com
NewCap
Investor Relations
Nicolas Fossiez
Tel: 01 44 71 94 94
implanet@newcap.eu
NewCap
Media Relations
Arthur Rouillé
Tel: 01 44 71 94 94
implanet@newcap.eu
Source: